DW Insights & Inquiries
This rare disorder has a good prognosis. Whether it falls under the spectrum of cutaneous polyarteritis nodosa, or is a disease sui generis, will be determined when the etiology of these diseases is ascertained.
LAG-3 inhibition by relatlimab is the newest checkpoint inhibitor that has demonstrated efficacy in advanced melanoma when used in combination with nivolumab.
Although eruptive pseudoangiomatosis is usually encountered in children with viral syndrome, there are increasing reports in adults, including those with COVID-19, vaccination against SARS-CoV-19, and other conditions.
Oxymetazoline has been used for its vasoconstrictive properties in rosacea, erythromlelagia, and post-acne erythema. The α-adrenergic receptors in the Muller muscle allow the drug to benefit patients with ptosis.
In all likelihood, Zuska disease is a localized form of hidradenitis suppurativa. Should Pagetoid cells be observed histologically, Toker cell hyperplasia — a benign condition — must be considered.
Late-onset neutropenia has been increasingly recognized in patients receiving rituximab. Dermatologists need to be cognizant of this adverse reaction and monitor patients carefully during rituximab therapy.
To improve the practice of dermatology, while being stimulating, practical, thought-provoking, and enlightening by offering critical perspectives on current dermatologic literature meant to be used in the clinic today and in the future.
Explore Dermatology World Insights and Inquiries clinical topics by practice focus, condition, and medical journal source.
All content solely developed by the American Academy of Dermatology
The American Academy of Dermatology gratefully acknowledges support from Incyte Dermatology.
